单细胞多组学揭示HBV-ACLF进展的动态免疫发病机制
本研究对17例住院HBV-ACLF患者(进展/稳定/恢复6/5/6)及15例对照(肝硬化、慢性乙肝、健康各5例)的外周血单个核细胞进行单细胞RNA测序和单细胞蛋白组学分析,并结合体内外功能验证。结果揭示VCAN+CD14+单核细胞在ACLF-1期扩增驱动早期炎症风暴,凋亡肝细胞诱导CXCR2+中性粒细胞和CD163+单核细胞增多并与疾病恶化相关,CXCR2+中性粒细胞抑制细胞毒性T细胞,药理学抑制CXCR2可改善小鼠ACLF。
要点
- VCAN+CD14+单核细胞受HBV复发刺激在ACLF-1期扩增,驱动早期炎症风暴。
- 凋亡肝细胞诱导CXCR2+中性粒细胞和CD163+单核细胞增多,标志疾病恶化。
- 抑制CXCR2可减少中性粒细胞浸润、恢复细胞毒性T细胞并改善小鼠ACLF。
核心结论
- 纵向多组学揭示HBV-ACLF免疫反应动态演变,鉴定出6个免疫细胞模块可用于患者分层和预后预测。
研究设计与样本
- 对17例住院HBV-ACLF患者(进展/稳定/恢复各6/5/6例)和15例对照(肝硬化、慢性乙肝、健康各5例)共45份样本的外周血单个核细胞行单细胞RNA测序和单细胞蛋白组学,并在体内外验证功能机制。
主要发现
- VCAN+CD14+单核细胞干扰素刺激基因激活、炎症功能增强,受HBV复发刺激在ACLF-1期扩增,驱动早期炎症风暴。
- 凋亡肝细胞主要诱导高炎症性CXCR2+中性粒细胞和CD163+单核细胞,在进展性ACLF患者中富集,是疾病恶化的重要标志。
- 细胞毒性T细胞功能受损且在进展性患者中显著减少,CXCR2+中性粒细胞具有免疫抑制活性并诱导细胞毒性T细胞耗竭。
- 药理学抑制CXCR2显著减少中性粒细胞浸润、恢复细胞毒性T细胞,在ACLF小鼠中显示治疗效应。
- 鉴定出6个免疫细胞模块(CMs)用于患者分层,CM2和CM6对疾病结局有强预测价值,CM3提示潜在早期治疗窗口。
临床怎么用
- VCAN+CD14+单核细胞、CXCR2+中性粒细胞和CD163+单核细胞可作为HBV-ACLF疾病进展的监测标志。
- CXCR2+中性粒细胞和细胞毒性T细胞耗竭是潜在治疗靶点,抑制CXCR2在动物模型中显示治疗效应。
- 基于6个免疫细胞模块的分层(尤其CM2、CM6)可用于预测疾病结局,CM3提示早期干预窗口。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute-on-chronic liver failure (ACLF) is a life-threatening syndrome involving dysfunction of multiple immune cell types. OBJECTIVE: This study aimed to comprehensively depict the dynamic trajectory of immune responses throughout the disease course of HBV-related ACLF (HBV-ACLF). DESIGN: Single-cell RNA sequencing and single-cell proteomics were performed on the peripheral blood mononuclear cells of 45 samples from 17 patients who were hospitalised (progressive/stable/recovering course of HBV-ACLF, 6/5/6) and 15 control subjects (liver cirrhosis, chronic hepatitis B and healthy controls, 5/5/5). Functional and mechanistic experiments were validated in vivo and in vitro. RESULTS: Single-cell multiomics analysis revealed specific changes in the peripheral immune response in ACLF. VCAN+CD14+-monocytes with activated interferon-stimulated genes and enhanced inflammatory functions, stimulated by HBV relapse and expanded in ACLF-1, fuelling early inflammatory storm. The subsequent apoptotic hepatocytes predominantly induce hyperinflammatory C-X-C motif chemokine receptor 2 (CXCR2)+-neutrophils and CD163+-monocytes, enriching in patients with progressive ACLF and serving as significant markers of disease deterioration. Cytotoxic T-cells were functionally impaired and significantly decreased in progressive patients. CXCR2+-neutrophils exhibited immunosuppressive activity and induced the exhaustion of cytotoxic T-cells. Pharmacological inhibition of CXCR2 significantly reduced neutrophils infiltration, restored cytotoxic T-cells and showed therapeutic effect in ACLF mice. Six immune cellular modules (CMs) were identified for patient stratification, with CM2 and CM6 showing strong predictive value for disease outcomes, and CM3 indicating a potential early therapeutic window. CONCLUSION: Our longitudinal multiomics study revealed the dynamic evolution of the immune response in HBV-ACLF and characterised diverse immune patterns for the future precise management and therapeutic intervention.
引用
- Liang X, Luo J, Zhou Q, et al. Single-cell multimodal analysis reveals the dynamic immunopathogenesis of HBV-ACLF progression. Gut. 2026. PMID: 40841166. doi:10.1136/gutjnl-2024-333308
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。